368 related articles for article (PubMed ID: 32233107)
21. Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101.
Uemura M; Tomita Y; Miyake H; Hatakeyama S; Kanayama HO; Numakura K; Takagi T; Kato T; Eto M; Obara W; Uemura H; Choueiri TK; Motzer RJ; Fujii Y; Kamei Y; Umeyama Y; di Pietro A; Oya M
Cancer Sci; 2020 Mar; 111(3):907-923. PubMed ID: 31883418
[TBL] [Abstract][Full Text] [Related]
22. High serum sodium predicts immunotherapy response in metastatic renal cell and urothelial carcinoma.
Klümper N; Cox A; Eckstein M; Kuppe C; Ritter M; Brossart P; Luetkens J; Hölzel M; Stein J; Saal J
Eur J Cancer; 2024 Jun; 204():114089. PubMed ID: 38703618
[TBL] [Abstract][Full Text] [Related]
23. Combination Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Alam MU; Jazayeri SB; Gautam S; Norez D; Kumar J; Tanneru K; Nguyen S; Costa J; Bandyk M; Ganapathi HP; Koochekpour S; Balaji KC
Am J Clin Oncol; 2020 Jul; 43(7):477-483. PubMed ID: 32251121
[TBL] [Abstract][Full Text] [Related]
24. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α.
Tsimafeyeu I; Zart JS; Chung B
BJU Int; 2013 Jul; 112(1):32-8. PubMed ID: 23746142
[TBL] [Abstract][Full Text] [Related]
25. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
Thompson Coon J; Hoyle M; Green C; Liu Z; Welch K; Moxham T; Stein K
Health Technol Assess; 2010 Jan; 14(2):1-184, iii-iv. PubMed ID: 20028613
[TBL] [Abstract][Full Text] [Related]
26. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
27. Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer.
Adams S; Diéras V; Barrios CH; Winer EP; Schneeweiss A; Iwata H; Loi S; Patel S; Henschel V; Chui SY; Rugo HS; Emens LA; Schmid P
Ann Oncol; 2020 May; 31(5):582-589. PubMed ID: 32178964
[TBL] [Abstract][Full Text] [Related]
28. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
Eichelberg C; Vervenne WL; De Santis M; Fischer von Weikersthal L; Goebell PJ; Lerchenmüller C; Zimmermann U; Bos MM; Freier W; Schirrmacher-Memmel S; Staehler M; Pahernik S; Los M; Schenck M; Flörcken A; van Arkel C; Hauswald K; Indorf M; Gottstein D; Michel MS
Eur Urol; 2015 Nov; 68(5):837-47. PubMed ID: 25952317
[TBL] [Abstract][Full Text] [Related]
29. Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade.
Motzer RJ; Banchereau R; Hamidi H; Powles T; McDermott D; Atkins MB; Escudier B; Liu LF; Leng N; Abbas AR; Fan J; Koeppen H; Lin J; Carroll S; Hashimoto K; Mariathasan S; Green M; Tayama D; Hegde PS; Schiff C; Huseni MA; Rini B
Cancer Cell; 2020 Dec; 38(6):803-817.e4. PubMed ID: 33157048
[TBL] [Abstract][Full Text] [Related]
30. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.
Rini BI; Bellmunt J; Clancy J; Wang K; Niethammer AG; Hariharan S; Escudier B
J Clin Oncol; 2014 Mar; 32(8):752-9. PubMed ID: 24297945
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and Safety of Checkpoint Inhibitors in Clear Cell Renal Cell Carcinoma: A Systematic Review of Clinical Trials.
Farrukh M; Ali MA; Naveed M; Habib R; Khan H; Kashif T; Zubair H; Saeed M; Butt SK; Niaz R; Garg I; Fatima A; Aiman W
Hematol Oncol Stem Cell Ther; 2023 Apr; 16(3):170-185. PubMed ID: 37023219
[TBL] [Abstract][Full Text] [Related]
32. 89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment.
Oosting SF; Brouwers AH; van Es SC; Nagengast WB; Oude Munnink TH; Lub-de Hooge MN; Hollema H; de Jong JR; de Jong IJ; de Haas S; Scherer SJ; Sluiter WJ; Dierckx RA; Bongaerts AH; Gietema JA; de Vries EG
J Nucl Med; 2015 Jan; 56(1):63-9. PubMed ID: 25476536
[TBL] [Abstract][Full Text] [Related]
33. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
[TBL] [Abstract][Full Text] [Related]
34. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.
Rini BI; Halabi S; Rosenberg JE; Stadler WM; Vaena DA; Ou SS; Archer L; Atkins JN; Picus J; Czaykowski P; Dutcher J; Small EJ
J Clin Oncol; 2008 Nov; 26(33):5422-8. PubMed ID: 18936475
[TBL] [Abstract][Full Text] [Related]
35. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.
Feldman DR; Baum MS; Ginsberg MS; Hassoun H; Flombaum CD; Velasco S; Fischer P; Ronnen E; Ishill N; Patil S; Motzer RJ
J Clin Oncol; 2009 Mar; 27(9):1432-9. PubMed ID: 19224847
[TBL] [Abstract][Full Text] [Related]
36. Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell Carcinoma.
Varkaris A; Xu W; Davis RB; Healy B; McDermott DF
Clin Genitourin Cancer; 2020 Jun; 18(3):179-184.e3. PubMed ID: 32144046
[TBL] [Abstract][Full Text] [Related]
37. Sunitinib in patients with metastatic renal cell carcinoma.
Motzer RJ; Rini BI; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Merchan JR; Wilding G; Ginsberg MS; Bacik J; Kim ST; Baum CM; Michaelson MD
JAMA; 2006 Jun; 295(21):2516-24. PubMed ID: 16757724
[TBL] [Abstract][Full Text] [Related]
38. Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up.
Tomita Y; Kondo T; Kimura G; Inoue T; Wakumoto Y; Yao M; Sugiyama T; Oya M; Fujii Y; Obara W; Motzer RJ; Uemura H
Jpn J Clin Oncol; 2020 Jan; 50(1):12-19. PubMed ID: 31633185
[TBL] [Abstract][Full Text] [Related]
39. Integrating On-Treatment Modified Glasgow Prognostic Score and Imaging to Predict Response and Outcomes in Metastatic Renal Cell Carcinoma.
Saal J; Bald T; Eckstein M; Ralser DJ; Ritter M; Brossart P; Grünwald V; Hölzel M; Ellinger J; Klümper N
JAMA Oncol; 2023 Aug; 9(8):1048-1055. PubMed ID: 37347489
[TBL] [Abstract][Full Text] [Related]
40. Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness.
Thompson Coon JS; Liu Z; Hoyle M; Rogers G; Green C; Moxham T; Welch K; Stein K
Br J Cancer; 2009 Jul; 101(2):238-43. PubMed ID: 19568242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
